AlchiMedics Overview

  • Founded
  • 2007
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 2
Employees
  • Latest Deal Type
  • M&A

AlchiMedics General Information

Description

Developer of electro-grafting technology for implantable biomedical applications. The company develops technology that is used for the fast healing post drug eluting stent implantation.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Surgical Devices
Other Industries
Medical Supplies
Acquirer
Simmed Asia
Primary Office
  • Zone Industrielle De La Bonde
  • 15 Rue du Buisson aux Fraises
  • 91300 Massy
  • France
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

AlchiMedics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 01-Dec-2012 00.000 Completed Startup
1. Early Stage VC (Series A) 01-Mar-2007 00.000 00.000 Completed Startup
To view AlchiMedics’s complete valuation and funding history, request access »

AlchiMedics Executive Team (1)

Name Title Board Seat Contact Info
Christophe Bureau Ph.D Founder & Chief Executive Officer
To view AlchiMedics’s complete executive team members history, request access »

AlchiMedics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AlchiMedics Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Auriga Partners (Paris) Venture Capital Minority 000 0000 000000 0
Idinvest Partners PE/Buyout Minority 000 0000 000000 0
To view AlchiMedics’s complete investors history, request access »